文献速递心境障碍精神分裂症与精神病性障碍会诊联络精神医学

GLP-1受体激动剂在严重精神疾病患者中的死亡与心血管结局

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.
PubMed 文献 · JAMA Psychiatry · 2026-08-26

这项靶试验模拟研究基于TriNetX电子健康记录网络,比较GLP-1受体激动剂与SGLT2抑制剂起始治疗对严重精神疾病(SMI)及非SMI成人的全因死亡和主要心血管事件影响,发现GLP-1受体激动剂组死亡风险更低,且在SMI亚组绝对获益更大。

要点

  • 在SMI患者中,GLP-1受体激动剂起始治疗4年全因死亡风险低于SGLT2抑制剂(HR 0.76)。
  • SMI合并2型糖尿病患者中,司美格鲁肽与3点MACE风险降低相关(HR 0.77)。
  • 1年随访即见死亡风险降低,10年探索性分析显示各SMI亚组获益一致。

核心结论

  • 在严重精神疾病患者中,起始GLP-1受体激动剂治疗与较SGLT2抑制剂更低的死亡和心血管事件风险相关,绝对获益更大。

研究设计与样本

  • 采用TriNetX Analytics Network电子健康记录网络进行回顾性靶试验模拟,使用新用户、活性对照设计,经倾向评分匹配,分别构建精神疾病和非精神疾病队列。
  • 主要4年分析纳入1 528 230名成人(764 115对匹配),其中SMI匹配对195 184对,非SMI匹配对568 931对。

主要发现

  • SMI患者中,GLP-1受体激动剂组4年死亡率为4.91%(9585/195 184),SGLT2抑制剂组为6.45%(12 584/195 184),HR 0.76(95% CI 0.74-0.78),ARD -1.54个百分点(95% CI -1.68至-1.39),P < .001。
  • SMI合并2型糖尿病患者中,司美格鲁肽起始治疗相比SGLT2抑制剂与3点MACE风险降低相关(HR 0.77,95% CI 0.76-0.79),5点MACE、心肌梗死、卒中、心力衰竭和冠状动脉旁路移植术风险亦降低。
  • 1年SMI匹配队列中,GLP-1受体激动剂组死亡率为1.46%(2898/198 065),SGLT2抑制剂组为2.84%(5624/198 065),RR 0.52(95% CI 0.49-0.54),ARD -1.38个百分点(95% CI -1.47至-1.29),P < .001。
  • 10年探索性分析中,2型糖尿病患者起始司美格鲁肽相比SGLT2抑制剂,重性抑郁障碍组死亡RR 0.55(95% CI 0.53-0.56),双相障碍组RR 0.57(95% CI 0.51-0.63),精神分裂症组RR 0.67(95% CI 0.59-0.75),均P < .001。

关键数值与推荐

  • 主要结局为4年全因死亡,关键次要结局为1年死亡,其他结局包括3点和5点MACE及个体心血管终点。

临床怎么用

  • 对于合并2型糖尿病或心血管高风险的严重精神疾病患者,GLP-1受体激动剂可能较SGLT2抑制剂带来更优的死亡和心血管获益。
  • 临床决策时可考虑优先选用司美格鲁肽或替尔泊肽,但需结合患者个体情况并等待前瞻性随机试验验证。

局限性

  • 本研究为回顾性靶试验模拟,存在未测量混杂可能,结果需前瞻性随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bipolar disorder, major depressive disorder, and schizophrenia are associated with substantial excess mortality, principally from cardiovascular disease. Identifying strategies to reduce this burden is a critical psychiatric priority. OBJECTIVE: To evaluate associations between initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors and all-cause mortality and major adverse cardiovascular events (MACEs) among adults with and without serious mental illness (SMI). DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective target trial emulation within the TriNetX Analytics Network, a multinational federated electronic health record network. Adults initiating GLP-1 RAs or SGLT2 inhibitors were included using a new-user, active-comparator design with propensity score matching and separate psychiatric and nonpsychiatric cohorts. The study included all available data in the TriNetX network through the most recent database refresh. Data were queried and analyzed in March 2026, with prespecified follow-up intervals of 1, 4, and 10 years. Additional subgroup analyses were conducted following peer review in May 2026. EXPOSURE: First-recorded GLP-1 RA vs SGLT2 inhibitor prescription. MAIN OUTCOMES AND MEASURES: The primary outcome was 4-year all-cause mortality; the key secondary outcome, 1-year mortality. Additional outcomes included 3- and 5-point MACEs and individual cardiovascular end points. Sensitivity analyses included diabetes stratification, exclusion of baseline heart failure and chronic kidney disease, and censoring at crossover. Exploratory analyses examined SMI subgroups, agent-specific effects, and combination therapy. RESULTS: For the primary 4-year analysis, 1 528 230 adults were propensity score matched (764 115 pairs; 195 184 pairs with serious mental illness [SMI] and 568 931 pairs without SMI). The mean [SD] age in the GLP-1RA and SGLT2 inhibitor groups was 60.5 [12.0] and 60.2 [13.3] years, respectively, in the SMI cohort and 60.9 [12.2] and 60.6 [13.0] years, respectively, in the non-SMI cohort; 112 911 [57.8%], 113 488 [58.1%], 251 679 [44.2%], and 260 480 [45.8%] were female, respectively. Among participants with SMI, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (9585 of 195 184 [4.91%] vs 12 584 of 195 184 [6.45%]; hazard ratio [HR], 0.76; 95% CI, 0.74-0.78; absolute risk difference [ARD], -1.54 percentage points; 95% CI, -1.68 to -1.39; P < .001). Among participants with SMI and type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower risks of 3-point MACE (HR, 0.77; 95% CI, 0.76-0.79), 5-point MACE, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting. In a separately matched 1-year SMI cohort, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (2898 of 198 065; 1.46% vs 5624 of 198 065; 2.84%; RR, 0.52; 95% CI, 0.49-0.54; ARD, -1.38 percentage points; 95% CI, -1.47 to -1.29; P < .001). In 10-year exploratory analyses among participants with type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower mortality in the major depressive disorder (RR, 0.55; 95% CI, 0.53-0.56), bipolar disorder (RR, 0.57; 95% CI, 0.51-0.63), and schizophrenia (RR, 0.67; 95% CI, 0.59-0.75) groups (all P < .001). The primary mortality association persisted across prespecified sensitivity analyses. CONCLUSIONS AND RELEVANCE: In this study, GLP-1 RA initiation was associated with lower mortality and cardiovascular events compared to SGLT2 inhibitor initiation, with greater absolute reductions in SMI. Benefits were evident within 1 year, consistent across SMI subgroups, and driven by semaglutide and tirzepatide. Prospective randomized trials are warranted.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. McIntyre RS, Zhang-James Y, Kwan ATH, et al. Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness. JAMA Psychiatry. 2026. PMID: 42647034. doi:10.1001/jamapsychiatry.2026.2574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。